Navigation Links
Alzheimer's Drug Discovery Foundation Funds ALS Biopharma to Develop Small Molecules for Alzheimer's Disease
Date:1/27/2011

NEW YORK, Jan. 27, 2011 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it has awarded a grant of $195,000 to ALS Biopharma, LLC to develop therapeutics targeted at clearing toxic proteins implicated in Alzheimer's disease.

(Logo: http://photos.prnewswire.com/prnh/20090805/DC57332LOGO)

The program will identify and develop small-molecule brain-penetrant inducers of heat shock protein 70 (Hsp70).  Hsp70 clears two proteins believed to be involved in Alzheimer's disease, the toxic form of tau protein and beta-amyloid.   The company first developed the Hsp70 program to clear insoluble protein deposits seen in amyotrophic lateral sclerosis (ALS).  

"We greatly appreciate the ADDF funding because it allows us to explore small-molecule regulation of the heat shock response to treat neurological disorders by taking advantage of our established competencies in pharmacology and medicinal chemistry," said Dr. Allen Reitz, CEO of ALS Biopharma.

"We are excited to support ALS Biopharma's innovative program in this target area," said Howard Fillit, MD, Executive Director of the ADDF.   "Small molecule therapeutics targeting Hsp70 would result in a disease-modifying therapy for Alzheimer's disease and could also be employed in related neurodegenerative diseases, such as ALS, Parkinson's and Huntington's."

About the Alzheimer's Drug Discovery Foundation (www.AlzDiscovery.org)

The ADDF (www.AlzDiscovery.org) is the only public charity whose sole mission is to accelerate the discovery and development of drugs to prevent, treat and cure Alzheimer's disease, related dementias and cognitive aging. Since 1998, the ADDF has granted more than $45 million to fund over 325 Alzheimer's drug discovery and development programs in academic centers and biotechnology companies in 17 countries. 

About ALS Biopharma, LLC (www.alsbiopharma.com)

ALS Biopharma, LLC (ALSBio) is an emerging biotechnology company located at the Pennsylvania Biotechnology Center in Doylestown, Pennsylvania.  ALSBio is an emerging biotechnology company dedicated to the discovery of therapeutics and diagnostics for the treatment of the debilitating neurological orphan indication of amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease) and related disorders such as Alzheimer's disease.  Modern methods in drug discovery are used including compound library synthesis and screening.  In partnership with top academic and industrial laboratories, ALSBio is researching both small molecule and biologic protein-based approaches to provide therapeutic relief to patients in need.


'/>"/>
SOURCE Alzheimer's Drug Discovery Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Diagenic Partners With DNAVision to Offer First Breast Cancer and Alzheimers Gene-Expression Blood Tests
2. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
3. Concentric Named Professional Agency of Record for Discovery Labs SURFAXIN(R)
4. ChanTest to Highlight the Worlds Largest Catalog of Ion Channel-Expressing Cell Lines and Discovery Services at Ion Channel Targets, Booth 5
5. Biotechnology & Drug Discovery Markets Push Up Demand for Lab Automation Products, According to a New Report by Global Industry Analysts
6. Assay Designs(TM), Inc. and the Spinal Muscular Atrophy Foundation Announce Collaboration To Accelerate the Discovery of New Therapeutics for Spinal Muscular Atrophy (SMA)
7. ChanTest to Highlight the Worlds Largest Catalog of Ion Channel-Expressing Cell Lines and Discovery Services at Assays & Cellular Targets Conference, Booth 11
8. Affitech Announces Second Milestone in Roche Antibody Discovery Collaboration
9. The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline
10. Update: The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline
11. deCODE Discovery Sheds Light on Risk of the Most Common Form of Skin Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" ... by its major shareholders, Clean Technology Fund I, LP ... States based venture capital funds which together ... (on a fully diluted, as converted basis), that they ... their entire equity holdings in Biorem to TUS Holdings ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. Hoffmann, ... faculty of the University of North Carolina Kenan-Flagler Business School effective ... at UNC Kenan-Flagler, with a focus on the school’s international efforts, leading classes ...
(Date:6/24/2016)... , ... June 24, 2016 , ... While the majority ... as the Cary 5000 and the 6000i models are higher end machines that use ... height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
Breaking Biology Technology:
(Date:6/22/2016)... On Monday, the Department of Homeland Security (DHS) issued ... the Biometric Exit Program. The Request for Information (RFI), ... that CBP intends to add biometrics to confirm when ... , in order to deter visa overstays, to ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/20/2016)... 20, 2016 Securus Technologies, a leading ... for public safety, investigation, corrections and monitoring announced ... it has secured the final acceptance by all ... Managed Access Systems (MAS) installed. Furthermore, Securus will ... be installed by October, 2016. MAS distinguishes between ...
(Date:6/15/2016)... , June 15, 2016 ... market report titled "Gesture Recognition Market by Application Market - Global ... 2016 - 2024". According to the report, the  global ... billion in 2015 and is estimated to grow ... 48.56 billion by 2024.  Increasing application ...
Breaking Biology News(10 mins):